Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial

• Published in: The American heart journal Vol. 173; pp. 94 - 101
• Main Authors: Sabatine, Marc S., Giugliano, Robert P., Keech, Anthony, Honarpour, Narimon, Wang, Huei, Liu, Thomas, Wasserman, Scott M., Scott, Robert, Sever, Peter S., Pedersen, Terje R.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.03.2016; Elsevier Limited
• Subjects: Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal, Humanized; Australia - epidemiology; Cardiovascular; Cardiovascular disease; Cardiovascular diseases; Cardiovascular Diseases - blood; Cardiovascular Diseases - epidemiology; Cardiovascular Diseases - prevention & control; Cholesterol, VLDL - blood; Cholesterol, VLDL - drug effects; Clinical trials; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage; Incidence; Injections, Subcutaneous; Lipids; Lipoproteins, LDL - blood; Lipoproteins, LDL - drug effects; Low density lipoprotein; Male; Morbidity; Norway - epidemiology; Proprotein Convertase 9; Proprotein Convertases - antagonists & inhibitors; Risk Assessment; Risk Factors; Serine Endopeptidases; Statins; Survival Rate - trends; Treatment Outcome; United Kingdom - epidemiology; United States - epidemiology; Vascular diseases; United Kingdom; Australia; Norway; United States

Despite current therapies, patients with vascular disease remain at high risk for major adverse cardiovascular events. Low-density lipoprotein cholesterol is a well-established modifiable cardiovascular risk factor. Evolocumab is a fully human monoclonal antibody inhibitor of proprotein convertase s...